Journal Article

DZNE-2025-00537

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png High Agreement Across Laboratories Between Different Alpha-Synuclein Seed Amplification Protocols.

Braeuer, S. (First author)DZNE* ; Weber, M. ; Deuschle, C.Extern* ; Julia, K. ; Concha-Marambio, L. ; Bernhardt, A. M.Extern* ; Kadam, V.DZNE* ; Mengel, D.DZNE* ; Ruf, W. P.DZNE* ; Kassubek, J.DZNE* ; Schniewind, I.DZNE* ; Kuhs, S.DZNE* ; Rossi, M. ; Parchi, P. ; Levin, J.DZNE* ; Danzer, K. M.DZNE* ; Synofzik, M.DZNE* ; Brockmann, K.DZNE* ; Falkenburger, B. (Last author)DZNE*

2025
Wiley-Blackwell Oxford [u.a.]

This record in other databases:    

Please use a persistent id in citations: doi:10.1111/ene.70165

Abstract: Seed amplification assays (SAA) detect alpha-synuclein (aSYN) pathology in patient biomatrices such as cerebrospinal fluid (CSF)-potentially even before clinical manifestations. As CSF-based SAA are approaching broader use in clinical trials and research, ensuring that different laboratories obtain the same results becomes increasingly important.In this cross-laboratory, cross-aSYN-recombinant substrate and cross-protocol round-robin test, we compared SAA results from a common set of 38 CSF samples measured independently in four research laboratories of the German Center for Neurodegenerative diseases. Three laboratories (A-C) used an assay protocol adapted from Parchi's group at ISNB (Bologna, Italy); laboratory D used an assay protocol adapted from Amprion Inc. Two different manufacturers of aSYN protein were used as substrates for the SAA reaction.Qualitative results were identical in at least three of the four laboratories for 37 out of 38 samples (20 positive, 17 negative). Fleiss Kappa for all four laboratories was 0.751 (z = 12, p < 0.001). For each laboratory, agreement with laboratory A was > 92%. For the number of positive replicates, Fleiss Kappa was 0.45 for a score of zero positive replicates and 0.42 for a score of four positive replicates.The qualitative SAA results showed a high level of agreement across research laboratories, aSYN monomers, and assay protocols. Small differences between laboratories were systematic, consistent with the notion that SAA reports biologically relevant properties. These results also underline that round-robin tests can be helpful in assessing and ensuring SAA quality across laboratories.

Keyword(s): Humans (MeSH) ; alpha-Synuclein: cerebrospinal fluid (MeSH) ; alpha-Synuclein: genetics (MeSH) ; Laboratories: standards (MeSH) ; Reproducibility of Results (MeSH) ; RT‐QuIC ; alpha‐synuclein ; method validation ; proficiency testing ; ring trial ; alpha-Synuclein

---

Contributing Institute(s):

1. Translational Parkinson Research (AG Falkenburger)
2. Clinical Research (Munich) (Clinical Research (Munich))
3. Parkinson Genetics (AG Gasser)
4. Mechanisms of Propagation (AG Danzer)
5. Clinical Study Center (Ulm) (Clinical Study Center (Ulm))
6. Clinical Research Platform (CRP) (AG Spottke)
7. Clinical Neurodegeneration (AG Levin)

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)
2. 352 - Disease Mechanisms (POF4-352) (POF4-352)

Appears in the scientific report 2025

---

Database coverage:
; ; ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DEAL Wiley ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---